Lupin Limited has officially notified stock exchanges about an upcoming board meeting scheduled to review its third-quarter financial performance for fiscal year 2026. The pharmaceutical company's announcement comes as part of its regulatory compliance obligations under SEBI guidelines.

Board Meeting Details

The company has scheduled its Board of Directors meeting for Thursday, February 12, 2026. The primary agenda includes consideration and approval of crucial financial documents for the reporting period.

Trading Window Restrictions

In accordance with insider trading prevention measures, Lupin has implemented a trading window closure affecting multiple stakeholder categories. The restriction period demonstrates the company's commitment to maintaining market integrity during sensitive financial disclosure periods.

Regulatory Compliance Framework

The board meeting notification aligns with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework ensures transparency and timely disclosure of material information to market participants.

The trading window closure follows the company's Code of Conduct for Prohibition of Insider Trading and SEBI's Prohibition of Insider Trading Regulations, 2015. These measures prevent potential misuse of unpublished price-sensitive information during the financial results preparation and announcement period.

Communication and Documentation

Company Secretary and Compliance Officer Amit Kumar Gupta has formally communicated this information to both major Indian stock exchanges. The notification was sent to the National Stock Exchange of India Limited (Symbol: LUPIN) and BSE Limited (Scrip Code: 500257), ensuring comprehensive market awareness of the scheduled corporate action.

Lupin Limited has announced the allotment of 169,140 equity shares under its Employee Stock Option Plan (ESOP), marking another step in the pharmaceutical company's employee incentive program. The allotment was approved by the company's Operations and Finance Committee during its meeting held on January 27, 2026.

Share Allotment Details

The company allotted 169,140 fully paid-up equity shares of ₹ 2 each to employees of the company and its subsidiaries. These shares were issued following the exercise of vested options granted under Lupin's stock option plans.

Impact on Share Capital

Following the ESOP allotment, Lupin's capital structure has been updated to reflect the increased shareholding base. The allotment has resulted in an expansion of the company's equity base.

Regulatory Compliance

The allotment was disclosed to stock exchanges in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both the National Stock Exchange of India Limited and BSE Limited about the share allotment.

The disclosure was signed by Amit Kumar Gupta, Company Secretary and Compliance Officer, ensuring proper regulatory adherence. This ESOP allotment represents Lupin's continued commitment to employee participation in the company's growth through equity-based compensation schemes.